China Pharma Holdings (CPHI) Operating Income (2010 - 2026)
China Pharma Holdings' (CPHI) quarterly Operating Income came in at -$1.1 million in Q1 2026, down 47.28% YoY from -$2.1 million in Q1 2025, and up 6.91% on a QoQ basis from -$1.2 million in Q4 2025.
China Pharma Holdings (CPHI) Operating Income (2010 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has 17 years of Operating Income data on file, last reported at -$1.1 million in Q1 2026.
- Quarterly Operating Income fell 47.28% year-over-year to -$1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.6 million (up 18.81% YoY) and the FY2025 annual result came in at -$3.2 million, up 29.41% from the prior year.
- Operating Income climbed to -$1.1 million in Q1 2026, from -$1.2 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$397479.0 in Q1 2023 to a low of -$1.4 million in Q2 2024.
- A 5-year average of -$896823.8 and a median of -$911718.0 in 2022 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2023 — Operating Income soared 56.4% — and 2024, when it plunged 204.95%.
- Tracing CPHI's Operating Income over 5 years: stood at -$1.2 million in 2022, then dropped by 1.32% to -$1.2 million in 2023, then decreased by 0.97% to -$1.2 million in 2024, then fell by 0.35% to -$1.2 million in 2025, then advanced by 6.91% to -$1.1 million in 2026.
- The last three Operating Income figures came in at -$1.1 million (Q1 2026), -$1.2 million (Q4 2025), and -$628145.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | -231.00 Mn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 837.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 1.26 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 330.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 6.30 Mn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 151.50 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 248.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | China Pharma Holdings | 42.14 Mn | 41.84 Mn | 83,566.00 | -1.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.12 Mn |
| Dec 31, 2025 | -1.20 Mn |
| Sep 30, 2025 | -628,145.00 |
| Jun 30, 2025 | -652,120.00 |
| Mar 31, 2025 | -758,618.00 |
| Dec 31, 2024 | -1.20 Mn |
| Sep 30, 2024 | -1.09 Mn |
| Jun 30, 2024 | -1.39 Mn |
| Mar 31, 2024 | -916,052.00 |
| Dec 31, 2023 | -1.18 Mn |
| Sep 30, 2023 | -713,542.00 |
| Jun 30, 2023 | -456,308.00 |
| Mar 31, 2023 | -397,479.00 |
| Dec 31, 2022 | -1.17 Mn |
| Sep 30, 2022 | -688,654.00 |
| Jun 30, 2022 | -779,593.00 |
| Mar 31, 2022 | -911,718.00 |
| Dec 31, 2021 | -648,690.00 |
| Sep 30, 2021 | -762,404.00 |
| Jun 30, 2021 | -752,948.00 |